Secure the BRIJ advantage
As BRIJ enters its next phase of growth, now is the ideal time to engage with Queensland’s fastest-growing centre for translational science. We welcome discussions with potential partners interested in research collaborations, industry expansion, laboratory and office leasing, institutional real estate investment, clinical trials, incubator or accelerator opportunities, venture capital deployment, access to specialist infrastructure and networking across our innovation ecosystem.
Research partnerships
Discover opportunities to work directly with BRIJ’s world-class research teams. Whether your interest lies in therapeutics, bioengineering, quantum computing or robotics, our partnership models provide early access to emerging technologies and market opportunities.
Build-out pipeline
For property and institutional investors, BRIJ offers a potential pipeline of health and life science developments in the state’s most established innovation ecosystem.
Capital & ventures
Position your capital to identify and invest in tomorrow’s success stories. We connect forward-thinking partners with promising ventures, providing deep sector expertise in transforming laboratory discoveries into commercial success.
Advanced facilities
Boost your research potential through flexible access to state-of-the-art laboratories and technical facilities. Scale your R&D operations without the capital burden of building your own infrastructure, with options from project-based collaboration to long-term partnerships.
Investment Incentives
Benefit from comprehensive government incentives including R&D tax rebates of up to 43.5%*. Australia’s pro-business environment and strategic research agenda direct public funding to critical areas – vaccine development, advanced manufacturing and quantum technology among them.
BRIJ enhances collaborators’ funding applications through direct assistance and the credibility gained from co-location in one of Australia’s most respected knowledge centres.
*BEDA State of the City Report, May 2024
